New COPD drug tozorakimab moves to Long-Term safety check
NCT ID NCT07566195
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing the long-term safety of a drug called tozorakimab in people with chronic obstructive pulmonary disease (COPD) who have had flare-ups in the past. About 82 participants who completed earlier studies will receive tozorakimab and be monitored for side effects. The goal is to see if the drug remains safe over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tozorakimab (a drug given as an injection)
What this could lead to
If successful, this could show that tozorakimab is safe for long-term use and help control COPD flare-ups.
What could go wrong
This is an open-label study with no placebo group, so results may be less reliable. It only includes people who already tolerated the drug in earlier trials, which may not reflect the broader COPD population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGAix-en-Provence, 13616, France
-
Research Site
RECRUITINGBrest, 29609, France
-
Research Site
WITHDRAWNColmar, 68024, France
-
Research Site
RECRUITINGGleizé, 69400, France
-
Research Site
RECRUITINGGrenoble, 38043, France
-
Research Site
RECRUITINGLyon, 69317, France
-
Research Site
RECRUITINGMarseille, 13015, France
-
Research Site
RECRUITINGMontpellier, 34295, France
-
Research Site
RECRUITINGPessac, 33600, France
-
Research Site
RECRUITINGPringy, 74374, France
-
Research Site
RECRUITINGQuimper, 29000, France
-
Research Site
RECRUITINGSaint-Herblain, 44800, France
-
Research Site
RECRUITINGToulouse, 31000, France